Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imigliptin - Sihuan Pharmaceutical Holdings Group

Next Previous
Drug Profile

Imigliptin - Sihuan Pharmaceutical Holdings Group

Alternative Names: 3853; Imigliptin dihydrochloride - Sihuan; KBP 3853

Latest Information Update: 29 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XuanZhu Pharma
  • Class Amines; Antihyperglycaemics; Benzene derivatives; Benzonitrile; Imidazoles; Piperidines; Pyridines
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 29 Sep 2020 No development reported - Phase-II for Type 2 diabetes mellitus in China (PO) (Xuanzhu Pharma website, September 2020)
  • 07 Jul 2020 Imigliptin - Sihuan Pharmaceutical Holdings Group is available for licensing as of 07 Jul 2020. http://www.xuanzhupharm.com/index.php?m=content&c=index&a=lists&catid=527 (XuanZhu Pharma pipeline, July 2020))
  • 30 Aug 2018 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top